Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Payer Support For Express Scripts’ “Transition” From Walgreens Shows Depth Of Interest In Drug Benefit Savings, PBM Says

This article was originally published in The Pink Sheet Daily

Executive Summary

During Express Scripts’ earnings call Feb. 23, CEO George Paz said the pharmacy benefit manager’s clients are willing to tolerate the potential inconvenience of a smaller pharmacy network, without Walgreens, because it can save them real money.

You may also be interested in...



Express Scripts Dispute With Walgreens Spotlights PBMs’ Thirst For Deeper Discounts

The contracting dispute between the drug chain and PBM may also presage tougher negotiations ahead for biopharmaceutical companies, particularly if Express Scripts is successful in its bid to acquire rival PBM Medco.

Express Scripts/Medco Merger Faces Longer Odds After FTC's Second Request

Following the Federal Trade Commission’s second request for additional information about Express Scripts Inc.'s proposed acquisition of Medco Health Solutions Inc., it is now statistically likely that the deal will be blocked or subject to a divestiture.

US Government Drug Pricing ‘Negotiation:’ Where We Go From Here

The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.

Topics

Related Companies

UsernamePublicRestriction

Register

PS073798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel